• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconGLP-1s

GLP-1s

Page 3 of 3
A person stands on a scale.
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
Ozempic and Wegovy medications side by side
Health
Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity
By The Associated Press, Kenya Hunter and Linley SandersJanuary 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health
Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Close up of RFK Jr. speaking against a blue background
Health
Health-care investors bank on Congress snarling RFK Jr.’s plans
By BloombergJanuary 17, 2025
Portrait of Crunch Fitness CEO Jim Rowley seated at Fortune's video studio.
Success
The CEO of Crunch Fitness doesn’t think there’s such a thing as work-life balance: ‘That’s for somebody who’s not fully committed’
By Jane Thier and Fortune EditorsJanuary 16, 2025
A Walgreens store exterior with people walking by on the street
Retail
Walgreens CEO describes drawback of anti-shoplifting strategy: ‘When you lock things up…you don’t sell as many of them’
By Hallie SteinerJanuary 14, 2025
1
  • 1
  • 2
  • 3
3
Most Popular
Economy
U.S. set to pay most for 30-year debt in quarter of a centuryplaceholder alt text
By Greg Ritchie and BloombergAugust 13, 2026
North America
Google cofounder Sergey Brin has now spent $100 million to fight California’s proposed billionaire tax—he could owe $13 billion if he losesplaceholder alt text
By Sasha RogelbergAugust 11, 2026
Personal Finance
Current price of oil as of August 13, 2026placeholder alt text
By Joseph HostetlerAugust 13, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.